FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282970683> ?p ?o ?g. }

• W4282970683 endingPage "1725" @default.
• W4282970683 startingPage "1725" @default.
• W4282970683 abstract "Abstract Purpose: Deeper understanding of immune landscape of DLBCL tumor microenvironment is critical for exploration and development of next generation immunotherapies. Although conventional immunohistochemical (IHC) analysis can provide information on the immune landscape or target expression, it is generally limited to single marker analysis. Advantages of multiplex fluorescence IHC (mFIHC) include the ability to assess different cell types, their spatial relationship as well as variable antigen expression on tumor cells. As such, we developed quantitative mFIHC panels using AQUA® (Automated Quantitative Analysis) technology to evaluate T and B cell populations and their functional status to generate detailed spatial information of immune checkpoint (IC) markers. mFIHC combined with hypothesis driven spatial profiling algorithms (e.g., AQUA Technology) were found to provide the most powerful predictors of immunotherapies in a systematic meta-analyses of over 8000 patients treated with PD1/L1 pathway blockers (Lu et al., JAMA Oncol 2019). Implementation of mFIHC coupled with robust image analysis may provide great insight into DLBCL immune surveillance, mechanism of resistance and patient stratification. Study Design: We designed two novel mFIHC assays to (1) characterize various B cell populations (CD19, CD20, CD22, PAX5, CD3, TIM3), and (2) evaluate T cell functional status (CD8, Granzyme B, PD1, PDL1, TIM3, Tumor). We successfully validated clinical grade mFIHC assays using automated staining (Leica Bond RX), imaging (Vectra Polaris) and analyses (AQUA Technology) workflow. Results: Sensitivity, accuracy and specificity were confirmed for all mFIHC assays on known positive and negative controls. Excellent reproducibility (less than 35% CV) and precision were observed across instruments, operators and independent experiments for all markers. Between these two panels, over 200 unique parameters were evaluated. The prevalence of CD19, CD20, CD22, and PAX5 ranged from 30% to &gt;90% positive for the DLBCL samples tested and were overall highly concordant with each other. Conclusion: The validated mFIHC assays examine B cell antigen expression in DLBCL and their interaction with CD3+ T cells and further characterize CD8+ T cells and immune checkpoint expression. These panels may be used to further understand the complex immune cell and tumor cell spatial biology in the context of clinical trials. Citation Format: James Paul Santos, Jacob Levy, Kristen Ruma, David Yang, Steve Woolfenden, Jimmie Lim, Xun Li, Ariana Valencia, James Deeds, Ramu Thiruvamoor, Xin Li, Emmanuel Pacia, Margaret McLaughlin, Thai Tran, Sarah Choi, Jennifer Bordeaux. Tissue-based biomarker analysis of DLBCL using multiplex immunofluorescence AQUA (Automated Quantitative Analysis) algorithms [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1725." @default.
• W4282970683 created "2022-06-17" @default.
• W4282970683 creator A5006434494 @default.
• W4282970683 creator A5015640756 @default.
• W4282970683 creator A5022526821 @default.
• W4282970683 creator A5024622024 @default.
• W4282970683 creator A5026462501 @default.
• W4282970683 creator A5026773157 @default.
• W4282970683 creator A5034292464 @default.
• W4282970683 creator A5041894254 @default.
• W4282970683 creator A5041976538 @default.
• W4282970683 creator A5042836487 @default.
• W4282970683 creator A5044554306 @default.
• W4282970683 creator A5053793254 @default.
• W4282970683 creator A5067271796 @default.
• W4282970683 creator A5077932903 @default.
• W4282970683 creator A5086202710 @default.
• W4282970683 creator A5091681636 @default.
• W4282970683 date "2022-06-15" @default.
• W4282970683 modified "2023-10-18" @default.
• W4282970683 title "Abstract 1725: Tissue-based biomarker analysis of DLBCL using multiplex immunofluorescence AQUA (Automated Quantitative Analysis) algorithms" @default.
• W4282970683 doi "https://doi.org/10.1158/1538-7445.am2022-1725" @default.
• W4282970683 hasPublicationYear "2022" @default.
• W4282970683 type Work @default.
• W4282970683 citedByCount "0" @default.
• W4282970683 crossrefType "journal-article" @default.
• W4282970683 hasAuthorship W4282970683A5006434494 @default.
• W4282970683 hasAuthorship W4282970683A5015640756 @default.
• W4282970683 hasAuthorship W4282970683A5022526821 @default.
• W4282970683 hasAuthorship W4282970683A5024622024 @default.
• W4282970683 hasAuthorship W4282970683A5026462501 @default.
• W4282970683 hasAuthorship W4282970683A5026773157 @default.
• W4282970683 hasAuthorship W4282970683A5034292464 @default.
• W4282970683 hasAuthorship W4282970683A5041894254 @default.
• W4282970683 hasAuthorship W4282970683A5041976538 @default.
• W4282970683 hasAuthorship W4282970683A5042836487 @default.
• W4282970683 hasAuthorship W4282970683A5044554306 @default.
• W4282970683 hasAuthorship W4282970683A5053793254 @default.
• W4282970683 hasAuthorship W4282970683A5067271796 @default.
• W4282970683 hasAuthorship W4282970683A5077932903 @default.
• W4282970683 hasAuthorship W4282970683A5086202710 @default.
• W4282970683 hasAuthorship W4282970683A5091681636 @default.
• W4282970683 hasConcept C11413529 @default.
• W4282970683 hasConcept C143998085 @default.
• W4282970683 hasConcept C203014093 @default.
• W4282970683 hasConcept C2776107976 @default.
• W4282970683 hasConcept C2781188995 @default.
• W4282970683 hasConcept C2781197716 @default.
• W4282970683 hasConcept C41008148 @default.
• W4282970683 hasConcept C502942594 @default.
• W4282970683 hasConcept C55493867 @default.
• W4282970683 hasConcept C60644358 @default.
• W4282970683 hasConcept C70721500 @default.
• W4282970683 hasConcept C71924100 @default.
• W4282970683 hasConcept C86803240 @default.
• W4282970683 hasConcept C8891405 @default.
• W4282970683 hasConceptScore W4282970683C11413529 @default.
• W4282970683 hasConceptScore W4282970683C143998085 @default.
• W4282970683 hasConceptScore W4282970683C203014093 @default.
• W4282970683 hasConceptScore W4282970683C2776107976 @default.
• W4282970683 hasConceptScore W4282970683C2781188995 @default.
• W4282970683 hasConceptScore W4282970683C2781197716 @default.
• W4282970683 hasConceptScore W4282970683C41008148 @default.
• W4282970683 hasConceptScore W4282970683C502942594 @default.
• W4282970683 hasConceptScore W4282970683C55493867 @default.
• W4282970683 hasConceptScore W4282970683C60644358 @default.
• W4282970683 hasConceptScore W4282970683C70721500 @default.
• W4282970683 hasConceptScore W4282970683C71924100 @default.
• W4282970683 hasConceptScore W4282970683C86803240 @default.
• W4282970683 hasConceptScore W4282970683C8891405 @default.
• W4282970683 hasIssue "12_Supplement" @default.
• W4282970683 hasLocation W42829706831 @default.
• W4282970683 hasOpenAccess W4282970683 @default.
• W4282970683 hasPrimaryLocation W42829706831 @default.
• W4282970683 hasRelatedWork W1971992579 @default.
• W4282970683 hasRelatedWork W2093409653 @default.
• W4282970683 hasRelatedWork W2725985716 @default.
• W4282970683 hasRelatedWork W3007075535 @default.
• W4282970683 hasRelatedWork W3030649553 @default.
• W4282970683 hasRelatedWork W3214265212 @default.
• W4282970683 hasRelatedWork W4241494942 @default.
• W4282970683 hasRelatedWork W4286629873 @default.
• W4282970683 hasRelatedWork W4313382565 @default.
• W4282970683 hasRelatedWork W4321368025 @default.
• W4282970683 hasVolume "82" @default.
• W4282970683 isParatext "false" @default.
• W4282970683 isRetracted "false" @default.
• W4282970683 workType "article" @default.